Welcome to our dedicated page for Inogen SEC filings (Ticker: INGN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Inogen Inc (INGN) SEC filings page on Stock Titan brings together the company’s regulatory disclosures as a Nasdaq-listed medical technology issuer. Inogen files annual reports on Form 10-K, quarterly reports on Form 10-Q, and current reports on Form 8-K, along with other required documents, providing detailed insight into its respiratory care business for the homecare setting.
In its periodic reports, Inogen presents financial statements and operating data covering sales and rental revenue, gross profit, operating expenses such as research and development, sales and marketing, and general and administrative costs, as well as net income or loss, cash flows, and balance sheet information. Supplemental tables may break out revenue by category, including business-to-business domestic and international sales and direct-to-consumer and rental activity, reflecting how its respiratory products reach patients and providers.
Current reports on Form 8-K document material events, such as the release of quarterly financial results and certain leadership or governance changes. For example, Inogen has used Form 8-K to furnish press releases reporting results for quarters ended March 31, June 30, and September 30, 2025, and to describe appointments and designations of executive officers.
On Stock Titan, these filings are updated as they become available from EDGAR and are paired with AI-powered summaries that explain key points in accessible language. Users can quickly see what Inogen reports about its respiratory product portfolio, revenue mix between sales and rentals, operating trends, and significant corporate developments without reading every line of each document.
Investors researching INGN can use this page to access 10-K and 10-Q filings for a structured view of Inogen’s financial condition and risk disclosures, and Form 8-K filings for timely updates on results of operations and notable corporate events, all supported by AI-generated highlights.
Inogen Inc CEO and President Kevin Raymond Merrill Smith reported multiple equity award transactions. On February 27, 2026, he received a grant of 90,000 restricted stock units, each representing a contingent right to one Inogen common share. Subject to continued service, one-third vests on March 1, 2027, with additional one-third portions vesting annually on the same date in subsequent years.
On March 1, 2026, performance-based and time-based restricted stock units vested, leading to share acquisitions and related tax-withholding dispositions. Vested awards included 28,334 and 30,012 shares from restricted stock units earned for 2025 financial performance, plus common stock awards of 685 and 32,725 shares. To cover tax liabilities on these vestings, the company withheld 16,374, 13,700, and 14,511 shares of common stock.
Inogen, Inc. files its annual report describing a respiratory-focused medical technology business built around portable oxygen concentrators, the Simeox airway-clearance device, Voxi 5 stationary oxygen concentrators, and Aurora CPAP masks. The company targets chronic respiratory conditions such as COPD, bronchiectasis and obstructive sleep apnea.
In 2025, Inogen generated $209.8 million of revenue in the United States, with about 45.1% from business-to-business sales, 29.5% from direct-to-consumer sales, and 25.4% from direct-to-consumer rentals. Approximately 39.8% of total 2025 revenue came from outside the United States, sold through distributors and large house accounts in 70 countries.
The report highlights a strategic collaboration with Yuwell to distribute Voxi 5 and Aurora masks in the United States and certain Asian markets, and the 2023 acquisition of Physio‑Assist, which added Simeox and expanded into airway clearance. Rental revenue depends heavily on Medicare programs, which supplied 61.9% of 2025 rental revenue and 9.5% of total revenue. As of December 31, 2025, Inogen employed 753 people worldwide and emphasizes innovation, regulatory compliance, and clinical evidence to support adoption of its products.
Inogen, Inc. reported modest growth but sharply better profitability for 2025 and announced a new share repurchase program. Full-year 2025 revenue rose 3.9% to $348.7 million, driven by 18.4% growth in international sales, while U.S. sales and rentals declined.
Net loss narrowed to $22.7 million from $35.9 million, and adjusted EBITDA turned positive at $2.7 million versus a $9.5 million loss in 2024. Cash, marketable securities, and restricted cash totaled $120.9 million with no debt. The board authorized a share repurchase program of up to $30 million through December 31, 2027.
For 2026, Inogen expects revenue of $366–$373 million, about 6% growth at the midpoint, and remains focused on further adjusted EBITDA improvement. Management highlighted new product launches, a strong balance sheet, and a strategic collaboration in China as key supports for future growth.
Inogen, Inc. filed a current report to let investors know it has released preliminary, unaudited revenue results for its fourth quarter and full year ended December 31, 2025. The company communicated these figures in a press release dated January 12, 2026, which is included as Exhibit 99.1. The filing emphasizes that the amounts are preliminary, have not been audited, and may change once the annual financial statements are completed, so they provide only a partial view of the company’s financial performance. Inogen also clarifies that the press release and related information are being furnished, not filed, which affects how they are treated under securities laws and in future SEC filings.
Inogen Inc's Chief Commercial Officer reports stock transactions linked to vesting restricted stock units. On December 1, 2025, the officer acquired 31,566 shares of common stock at an exercise price of $0 when a portion of a time-based restricted stock award vested. On the same day, 12,943 shares were withheld and disposed of at $6.95 per share to cover tax withholding obligations.
After these transactions, the officer directly owned 37,246 shares of Inogen common stock and held 31,565 restricted stock units. Each restricted stock unit represents the right to receive one share of Inogen common stock, with one-third of the units vesting on each anniversary of the December 1, 2023 vesting commencement date, subject to continued service.
Inogen Inc. disclosed an insider equity transaction involving its CEO and President, who also serves as a director. On December 1, 2025, a portion of a time-based restricted stock unit award vested, resulting in the acquisition of 28,334 shares of common stock at an exercise price of $0. To satisfy tax withholding obligations related to this vesting, 13,817 shares were withheld at a price of $6.95 per share. Following these transactions, the reporting person held 86,291 shares of Inogen common stock directly and 28,333 restricted stock units, which represent a contingent right to receive the same number of shares as they vest over time under the award’s vesting schedule.
Inogen, Inc. (INGN) reported Q3 2025 results with total revenue of $92.4 million, up from $88.8 million a year ago. Net loss was $5.3 million and diluted loss per share was $0.20. Gross profit was $41.3 million, essentially flat year over year, as higher sales were offset by rental margin pressure.
Operating expenses fell modestly, narrowing the loss from operations to $7.1 million from $7.8 million. For the nine months, revenue reached $266.9 million with a net loss of $15.6 million, an improvement from $26.1 million last year.
Liquidity remained solid with cash and cash equivalents of $106.5 million and marketable securities of $16.7 million. Operating cash flow was an outflow of $10.3 million year to date. The company received $27.2 million from a common stock private placement at $10.36 per share in Q1 and paid a $13.0 million acquisition earnout. In August, Inogen settled the APT dispute for $1.75 million plus $0.67 million in legal costs. Shares outstanding were 27,148,482 as of October 31, 2025.
Inogen, Inc. (INGN) furnished a press release with Q3 2025 results. The company submitted an 8‑K under Item 2.02 to provide its financial results for the quarter ended September 30, 2025. The press release is included as Exhibit 99.1 and is dated November 5, 2025.
The company states this information, including Exhibit 99.1, is furnished and not deemed filed under Section 18 of the Exchange Act. An Inline XBRL cover page is included as Exhibit 104. The report was signed by Michael Bourque, Executive Vice President, Chief Financial Officer and Treasurer.
Michael J. Bourque, EVP, CFO & Treasurer of Inogen Inc. (INGN), acquired 1,500 shares of the company's common stock on 09/01/2025 at a price of $7.99 per share under the 2014 Employee Stock Purchase Plan. After the purchase, Mr. Bourque directly beneficially owned 49,146 shares. The Form 4 was executed by Mary Wright as Attorney-in-Fact and dated 09/03/2025. The filing indicates the transaction was reported under Section 16 and that the purchase was made pursuant to a company plan; no derivatives, dispositions, or additional transactions are reported on this form.
Kevin P. Smith, Executive Vice President, Business Development, General Counsel and Secretary of Inogen Inc. (INGN), reported transactions on September 1, 2025 that changed his beneficial ownership. He purchased 1,500 shares under the companys 2014 Employee Stock Purchase Plan at $7.99 per share and received 18,135 restricted stock units (each representing one share) that vested in part on that date. To satisfy tax withholding on a portion of the vested awards, 8,043 shares were withheld. After these transactions Mr. Smith beneficially owns 36,271 shares.
The restricted stock units vest in three equal annual tranches, with one-third vested on September 1, 2025 and the remainder subject to continued service on the same annual date.